Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › NBIX

RICE HALL JAMES & ASSOCIATES, LLC position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 97,563 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$13.8M, representing 0.73% of its reported portfolio and ranking #43 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)97.56K sh
Reported value held$13.84M
Portfolio Weight0.73%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's NBIX position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in NBIX in Q3 2023 at 132,213 shares (US$14.9M). The position peaked in Q1 2024 at 126,421 shares, worth US$17.4M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 1 time(s), trimmed it 9 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 97,563 shares valued at US$13.8M — a reduction of -2,632 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 132.21K $14.87M New
Q4 2023 131.62K $17.34M Hold
Q1 2024 126.42K $17.44M Reduce
Q2 2024 118.11K $16.26M Reduce
Q3 2024 117.42K $13.53M Reduce
Q4 2024 110.63K $15.10M Reduce
Q1 2025 109.67K $12.13M Reduce
Q2 2025 108.38K $13.62M Reduce
Q3 2025 99.47K $13.96M Reduce
Q4 2025 98.02K $13.90M Reduce
Q1 2026 99.99K $13.17M Add
Q2 2026 100.19K $16.89M Hold
Q3 2026 97.56K $13.84M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 29 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M), RTW INVESTMENTS, LP (US$133.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held NBIX?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in NBIX?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 97.56K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $13.84M, representing 0.73% of its reported portfolio and ranking #43.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling NBIX?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in NBIX. The position peaked in Q1 2024 at 126.42K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Vestal Point Capital, LP, RTW INVESTMENTS, LP, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.